Drugs / Bacillus Calmette-Guerin (BCG)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05943106 | Aug 2023 → Jun 2025 overdue | urinary bladder cancer | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guerin (BCG) | “A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk...” NCT05943106 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05943106 ↗ |
| Route | Other | “via intravesical” NCT05943106 ↗ |